News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
584,667 Results
Type
Article (43565)
Company Profile (173)
Press Release (540915)
Multimedia
Podcasts (130)
Webinars (17)
Section
Business (163679)
Career Advice (1632)
Deals (28209)
Drug Delivery (127)
Drug Development (74933)
Employer Resources (123)
FDA (12818)
Job Trends (11375)
News (284641)
Policy (26666)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (1851)
Accelerated approval (26)
Adcomms (30)
Allergies (126)
Alliances (44049)
ALS (149)
Alzheimer's disease (1400)
Antibody-drug conjugate (ADC) (296)
Approvals (13028)
Artificial intelligence (396)
Autoimmune disease (146)
Automation (20)
Bankruptcy (250)
Best Places to Work (8303)
BIOSECURE Act (20)
Biosimilars (191)
Biotechnology (85)
Bladder cancer (131)
Brain cancer (52)
Breast cancer (475)
Cancer (3908)
Cardiovascular disease (363)
Career advice (1372)
Career pathing (38)
CAR-T (252)
CDC (34)
Celiac Disease (2)
Cell therapy (612)
Cervical cancer (26)
Clinical research (64539)
Collaboration (1419)
Company closure (5)
Compensation (666)
Complete response letters (63)
COVID-19 (2388)
CRISPR (70)
C-suite (733)
Cystic fibrosis (124)
Data (5356)
Decentralized trials (2)
Denatured (29)
Depression (136)
Diabetes (410)
Diagnostics (4082)
Digital health (26)
Diversity (10)
Diversity, equity & inclusion (35)
Drug discovery (217)
Drug pricing (207)
Drug shortages (33)
Duchenne muscular dystrophy (196)
Earnings (60866)
Editorial (59)
Employer branding (16)
Employer resources (117)
Events (93405)
Executive appointments (847)
FDA (15269)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (9)
Frontotemporal dementia (14)
Funding (1147)
Gene editing (154)
Generative AI (36)
Gene therapy (499)
GLP-1 (988)
Government (3571)
Grass and pollen (6)
Guidances (309)
Healthcare (11948)
HIV (53)
Huntington's disease (40)
IgA nephropathy (79)
Immunology and inflammation (257)
Immuno-oncology (51)
Indications (95)
Infectious disease (2625)
Inflammatory bowel disease (166)
Inflation Reduction Act (13)
Influenza (106)
Intellectual property (204)
Interviews (262)
IPO (11550)
IRA (54)
Job creations (3352)
Job search strategy (1174)
JPM (61)
Kidney cancer (16)
Labor market (72)
Layoffs (504)
Leadership (31)
Legal (6394)
Liver cancer (71)
Longevity (9)
Lung cancer (543)
Lymphoma (360)
Machine learning (28)
Management (44)
Manufacturing (683)
MASH (164)
Medical device (7140)
Medtech (7170)
Mergers & acquisitions (17490)
Metabolic disorders (1201)
Multiple sclerosis (149)
NASH (22)
Neurodegenerative disease (277)
Neuropsychiatric disorders (90)
Neuroscience (2507)
Neurotech (1)
NextGen: Class of 2026 (4324)
Non-profit (2514)
Now hiring (53)
Obesity (609)
Opinion (295)
Ovarian cancer (134)
Pain (187)
Pancreatic cancer (165)
Parkinson's disease (245)
Partnered (27)
Patents (392)
Patient recruitment (400)
Peanut (44)
People (53787)
Pharmaceutical (83)
Pharmacy benefit managers (33)
Phase 1 (20063)
Phase 2 (28285)
Phase 3 (21481)
Pipeline (4470)
Policy (287)
Postmarket research (2334)
Preclinical (7786)
Press Release (46)
Prostate cancer (191)
Psychedelics (44)
Radiopharmaceuticals (253)
Rare diseases (753)
Real estate (4930)
Recruiting (52)
Regulatory (20411)
Reports (30)
Research institute (1774)
Resumes & cover letters (247)
Rett syndrome (13)
RNA editing (15)
RSV (65)
Schizophrenia (147)
Series A (189)
Series B (204)
Service/supplier (9)
Sickle cell disease (92)
Special edition (25)
Spinal muscular atrophy (161)
Sponsored (30)
Startups (3458)
State (2)
Stomach cancer (15)
Supply chain (91)
Tariffs (97)
The Weekly (99)
Vaccines (876)
Venture capital (89)
Weight loss (432)
Women's health (58)
Worklife (16)
Date
Today (147)
Last 7 days (449)
Last 30 days (1605)
Last 365 days (23616)
2026 (2569)
2025 (23829)
2024 (27204)
2023 (30415)
2022 (40199)
2021 (43084)
2020 (39943)
2019 (32462)
2018 (24994)
2017 (27894)
2016 (28792)
2015 (34094)
2014 (27293)
2013 (23381)
2012 (24758)
2011 (24775)
2010 (22583)
Location
Africa (745)
Alabama (58)
Alaska (3)
Arizona (179)
Arkansas (11)
Asia (42429)
Australia (6432)
California (8106)
Canada (2584)
China (1045)
Colorado (351)
Connecticut (337)
Delaware (259)
Europe (85581)
Florida (1269)
Georgia (251)
Hawaii (2)
Idaho (32)
Illinois (673)
India (64)
Indiana (371)
Iowa (11)
Japan (405)
Kansas (107)
Kentucky (32)
Louisiana (13)
Maine (29)
Maryland (987)
Massachusetts (6084)
Michigan (187)
Minnesota (442)
Mississippi (5)
Missouri (69)
Montana (23)
Nebraska (20)
Nevada (93)
New Hampshire (31)
New Jersey (2509)
New Mexico (25)
New York (2251)
North Carolina (1174)
North Dakota (4)
Northern California (3966)
Ohio (209)
Oklahoma (12)
Oregon (30)
Pennsylvania (1609)
Puerto Rico (23)
Rhode Island (35)
South America (1054)
South Carolina (33)
Southern California (3243)
Tennessee (94)
Texas (1159)
United States (29329)
Utah (191)
Virginia (219)
Washington D.C. (70)
Washington State (708)
West Virginia (2)
Wisconsin (73)
Wyoming (1)
584,667 Results for "pharma two b ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ayrmid Pharma Ltd Announces Additional Positive Results for Omisirge(R) in Treating Severe Aplastic Anemia (SAA) Presented at TANDEM
February 5, 2026
·
4 min read
Press Releases
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
January 22, 2026
·
13 min read
Press Releases
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunityPatrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors
September 2, 2025
·
10 min read
Press Releases
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
December 8, 2025
·
10 min read
Mergers & acquisitions
Halozyme’s $900M Elektrofi Buyout Brings Two Big Pharma Partners Together
Both Halozyme and Elektrofi have partnered with several Big Pharma companies to provide drug delivery technologies.
October 2, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates
January 5, 2026
·
14 min read
Press Releases
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
October 14, 2025
·
10 min read
Press Releases
Recludix Pharma to Present at Two Investor Conferences in November 2025
November 4, 2025
·
1 min read
Press Releases
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
February 10, 2026
·
14 min read
Press Releases
Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President
December 2, 2025
·
14 min read
1 of 58,467
Next
